Clinuvel Pharmaceuticals Ltd (CUV) — Capital Reinvestment Ratio
Clinuvel Pharmaceuticals Ltd (CUV) has a Capital Reinvestment Ratio of 0.01x as of December 2025, meaning it reinvests 0% of its operating cash flow (AU$12.52 Million) in capital expenditures (AU$149.47K). Check tangible equity quality of Clinuvel Pharmaceuticals Ltd to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Clinuvel Pharmaceuticals Ltd Capital Reinvestment Ratio (2017–2025)
This chart tracks Clinuvel Pharmaceuticals Ltd's Capital Reinvestment Ratio across 9 annual periods. For the full cash flow conversion analysis, see CUV cash flow conversion.
Annual Capital Reinvestment Ratio for Clinuvel Pharmaceuticals Ltd (2017–2025)
Year-by-year Capital Reinvestment Ratio for Clinuvel Pharmaceuticals Ltd from 2017 to 2025. See cash generation quality of Clinuvel Pharmaceuticals Ltd to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (AUD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.01x | AU$41.10 Million | AU$298.57K | ▼ -95.2% |
| 2024 | 0.15x | AU$37.05 Million | AU$5.58 Million | ▲ +440.6% |
| 2023 | 0.03x | AU$36.91 Million | AU$1.03 Million | ▲ +155.5% |
| 2022 | 0.01x | AU$39.87 Million | AU$434.44K | ▼ -75.4% |
| 2021 | 0.04x | AU$19.26 Million | AU$854.33K | ▼ -29.2% |
| 2020 | 0.06x | AU$14.19 Million | AU$888.83K | ▲ +348.8% |
| 2019 | 0.01x | AU$18.46 Million | AU$257.62K | ▲ +117.3% |
| 2018 | 0.01x | AU$11.69 Million | AU$75.12K | ▼ -5.6% |
| 2017 | 0.01x | AU$9.92 Million | AU$67.48K | — |